Citius Pharmaceuticals Inc. (NASDAQ:CTXR) Announce Expanded Access Protocol For IOTs Mino-Lok Solution

Citius Pharmaceuticals Inc. (NASDAQ:CTXR) has announced that it will offer healthcare providers free access to its Mino-Lok under an Expanded Access program as a way of easing burden related to the coronavirus pandemic.

Citius to treat infected central venous catheter under an Expanded Access Program

The company’s Mino-Lok can now treat a central venous catheter infected under the Expanded Access program, which will help minimize the possibility of replacement or removal. Because of the challenges that health facilities are facing, patients, healthcare workers, and the healthcare system stand a chance of massively benefiting from the free access to the Citius Min-Lok solution.

Myron Holubiak, the CEO of the company, indicated that already some of its investigators have indicated that once the FDA approves Min-Lok, they would use it’s considering the current environment.  The CEO added that the company is waiting for the final results of its investigational clinical trial before they can begin commercializing Min-Lok. Myron affirmed that they are confident the solution will benefit patients as well as ease burden on hospitals and healthcare system

Min-Lok to help avoid complication sin removing the infected catheter 

Citius’ Min-Lok solution is an antibiotic solution used in treating patients with catheter-related bloodstream infections in combination with the right systemic antibiotics. It helps in preserving central venous access and avoids morbidities and complications related to catheter reinsertion and removal.

Currently, Min-Lok is under the third phase of a clinical trial for central line-associated bloodstream infections (CLABSIs) treatment. In February this year, Citius indicated that the study was halfway in terms of subject enrolment. The solution can transform the standard of care that currently requires a procedure when reinserting to remove an infected catheter. Every year there are more than 500,000 CVS of 7 million that are used are infected and result in CLABSIs increasing the risk of patient morbidity as well as medical costs. Currently, there are no treatments that have been approved to salvage infected central venous catheters, and antibiotics cannot penetrate the bacteria-caused biofilm.